Loading…
The Union Health Ministry banned the manufacture, sale and distribution of 16 fixed-dose combination (FDC) drugs through a gazette notification dated 11 June 2026.
The action was taken under Section 26A of the Drugs and Cosmetics Act, 1940.
The grounds were a lack of therapeutic justification and potential risk to public health.
The banned list includes certain antibiotic combinations and dermatological products containing aloe vera and herbal ingredients.
State drug regulators and enforcement agencies have been directed to implement the ban strictly.
An FDC is a single dosage form — one tablet, capsule or syrup — containing two or more active ingredients in fixed proportions. Some FDCs are genuinely valuable: anti-tuberculosis and antiretroviral combinations reduce the number of pills a patient must take and make it far harder to accidentally take only part of a regimen, which is what breeds drug resistance. The problem arises with what regulators call irrational combinations, where ingredients are packed together without evidence that the mixture works better than the components taken separately. These carry real costs. The patient is exposed to the side effects of every ingredient regardless of whether each is needed; the fixed ratio prevents a doctor adjusting one component's dose; and where an antibiotic is included in a combination taken for minor complaints, the result is antibiotic exposure without clinical justification, which accelerates antimicrobial resistance.
Simple Analogy: A rational FDC is a combination lock where every wheel is needed. An irrational one is a bundle where extra keys have been welded on — you carry them, you pay for them, and occasionally one of them damages the door.
The Kokate Committee is set up to examine FDCs approved by state licensing authorities without central clearance.
The Centre prohibits 328 FDCs following expert committee review, an action largely upheld by the courts.
156 more FDCs, including antibiotic, painkiller and multivitamin combinations, are banned after review.
16 further FDCs are prohibited under Section 26A for lack of therapeutic justification.
The parent statute governing the import, manufacture, distribution and sale of drugs and cosmetics in India.
Empowers the Central Government to prohibit the manufacture, sale or distribution of a drug in the public interest, the provision used for every FDC ban.
The national drug regulator, headed by the Drugs Controller General of India, which approves new drugs and FDCs.
License manufacture and sale within states; the historical practice of state-level FDC approvals without central clearance created the problem these bans address.
The statutory body advising central and state governments on technical matters under the Act.
GS Paper II > Issues relating to health, government policies and regulatory bodies
General Awareness > Health, science and government action
General Awareness > Government policy and regulation
General Awareness > General science and current affairs
A single dosage form containing two or more active drug ingredients in fixed proportions.
The provision of the Drugs and Cosmetics Act, 1940 empowering the Centre to ban a drug in the public interest.
Central Drugs Standard Control Organisation, India's national drug regulator.
Drugs Controller General of India, who heads CDSCO and approves new drugs.
The loss of effectiveness of antibiotics as microbes adapt, accelerated by unnecessary antibiotic use.